Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11479771
Antisense oligonucleotides for the treatment of eye disease
granted -
US 11479775
RNA targeting of mutations via suppressor tRNAs and deaminases
granted -
US 11479774
Methods of treating cancer harboring hemizygous loss of TP53
granted -
US 11479543
Heterocyclic RIP1 kinase inhibitors
granted -
US 11479599
Antibodies against SARS-CoV-2 and methods of using the same
granted -
US 11478422
Film formulations containing dexmedetomidine and methods of producing them
granted -
US 11478245
Surgical stapling device
granted -
US 11478420
Vaginal probiotic products and related processes
granted -
US 11478424
Mechanochemcial activated dry amorphisation by milling equilibrium between AP mesoporous silica
granted -
US 11478428
Combinations of beta-lactam compounds and probenecid and uses thereof
granted -
US 11478479
Dosing with an azolopyrimidine compound
granted -
US 11478430
Implantable medical devices for extended release of therapeutic agents
granted -
US 11478489
Selective accretion of cytoprotectant in radiation-sensitive tissues and uses thereof
granted -
US 11478502
Methods and compositions for administration of iron
granted -
US 11478497
Methods and compositions for treating eukaryotic infections via altering aggregation dynamics of Raptor/KOG1
granted -
US 11479770
Use of p38 inhibitors to reduce expression of DUX4
granted -
US 11479601
Antibodies specific to Sonic Hedgehog and method of use thereof
granted -
US 11479551
MTA-cooperative PRMT5 inhibitors
granted -
US 11478571
Synthetic hydrogel carriers for cellular structures, generation of organoids, and treatment of tissue injury
granted -
US 11478500
Anticancer compositions and methods for making and using them
granted -
US 11478517
Live attenuated recombinant HMPV with mutations in PDZ motifs of M2-2 protein, vaccine containing and use thereof
granted -
US 11478510
Chimeric antigen receptor and methods of use thereof
granted -
US 11478542
Immunogenic RSV polypeptides
granted -
US 11478541
Method for inactivating Zika virus and for determining the completeness of inactivation
granted -
US 11478556
Compositions and methods for treating or ameliorating neuroinflammation, neurodegeneration, neuropathic pain, and migraine
granted -
US 11479540
Nonpeptide somatostatin type 5 receptor agonists and uses thereof
granted -
US 11479530
Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
granted -
US 11478568
Radioactive cement
granted -
US 11479560
OX2R compounds
granted -
US 11479545
Compositions and methods for inhibiting phenyl triazole MLL1-WDR5 protein-protein interaction
granted -
US 11479576
Nucleic acid prodrugs
granted -
US 11479556
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
granted -
US 11479579
Therapeutic compounds and methods
granted -
US 11479595
Methods for modulating an immune response
granted -
US 11479617
Chelator-functionalized glycosaminoglycans
granted -
US 11479602
Methods of treating C5-associated diseases comprising administering anti-C5 antibodies
granted -
US 11479611
HLA-G specific chimeric antigen receptor, nucleic acid, HLA-G specific chimeric antigen receptor expression plasmid, HLA-G specific chimeric antigen receptor expressing cell, use thereof, and pharmaceutical composition for treating cancer
granted -
US 11478425
Extended release compositions comprising pyridostigmine
granted -
US 11479613
Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins
granted -
US 11479614
Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors
granted -
US 11479769
Technique for treating cancer using structurally-reinforced S-TuD
granted -
WO 2022226311
COMPOSITIONS NUTRITIONNELLES COMPRENANT DES OLIGOSACCHARIDES DE LAIT HUMAIN ET UN CONSTITUANT LIPIDIQUE DÉSIGNÉ D'AMÉLIORATION DE FONCTION PULMONAIRE
granted -
WO 2022225779
MÉTHODES ET COMPOSITIONS PERMETTANT DE FAVORISER LA CICATRISATION DE PLAIES
granted -
US 11484531
Methods for treating chronic obstructive pulmonary disease
granted -
US 11484573
Activin receptor type IIa variants and methods of use thereof
granted -
US 11485738
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted -
US 11484477
Dental adhesive material kit
granted -
US 11484603
Methods, systems, and compositions for inhibiting virulence of A/E family pathogens
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.